Clinical trial
Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With…
NCT00471211 · Prana Biotechnology Limited, Industry · Completed
Key facts
| NCT number | NCT00471211 |
|---|---|
| Title | Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease |
| Official title | A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease |
| Lead sponsor | Prana Biotechnology Limited, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | PBT2 |
| Enrollment | 80 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 9, 2007 |
| Last update posted | Jan 16, 2008 |
| Countries | Australia, Sweden |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: